Antengene’s ATG-101 Receives Orphan Drug Designation for Pancreatic Cancer
China-based biotech Antengene Corp., Ltd (HKG: 6996) has announced that its pipeline candidate ATG-101, a...
Ascletis Pharma and Roche Terminate Promotion Agreement for Pegasys
China-based Ascletis Pharma Inc. (HKG: 1672) has announced a supplementary agreement with Swiss pharmaceutical giant...
Apollomics Set to Merge with Maxpro Capital for Nasdaq Listing
Sino-US biotech Apollomics Inc. has revealed plans to merge with the special purpose acquisition company...
Everest Medicines Appoints Rogers Yongqing Luo as New CEO
China-based biotech Everest Medicines (HKG: 1952) has announced the appointment of a new CEO, Rogers...
Hainan’s Lecheng Zone Updates Special Drug Insurance List with Expanded Coverage
Hainan Boao Lecheng International Medical Tourism Pilot Zone has released an updated special drug insurance...
Shenzhen Vivolight Raises RMB 100 Million in Series D1 Financing for Laser Therapy Development
China-based laser diagnosis and treatment specialist Shenzhen Vivolight Medical Device & Technology Co., Ltd reportedly...
Best Covered Raises RMB 100 Million in Series A+ Funding for Cognitive Impairment Solution
Shanghai-based digital cognitive impairment solution provider Best Covered reportedly raised RMB 100 million (USD 14.2...
US Blocks Asymchem’s Acquisition of Snapdragon Chemistry
US authorities have intervened to block the purchase of US-based Contract Development and Manufacturing Organization...
Ascletis Completes Enrollment for HIV Functional Cure Study with PD-L1 Antibody ASC22
China-based Ascletis Pharma Inc. (HKG: 1672) announced that the clinical study of PD-L1 antibody ASC22...
CDE Issues Guidelines for Anti-Tumor ADC Clinical Development
The Center for Drug Evaluation (CDE) has released the “Technical Guidelines for Clinical Research and...
Eli Lilly Announces Global C-Suite Changes, New Leadership in China
US-based pharmaceutical giant Eli Lilly (NYSE: LLY) announced significant changes to its global C-suite. Julio...
China’s Policy Shifts Medical Device Procurement Toward Domestic Products
Local government policies in China have begun to direct public hospitals to prioritize the procurement...
Antengene Expands to Australia with New Melbourne Office
China-based biotech firm Antengene (HKG: 6996) announced the opening of its new office in Melbourne,...
Great Bay Bio Completes USD 15M Pre-Series B Financing to Advance AI Bioprocessing Platforms
Great Bay Bio (GBB), a Hong Kong-based biotechnology firm, announced the completion of a USD...
Zhonghong Pulin Partners with Shanghai Pharma for Logistics and Distribution
China-based Zhonghong Pulin Medical Product Co., Ltd (SHE: 300981) has entered into a partnership with...
Suzhou Jade Biomedical Secures USD 10 Million Series B Financing
China-based Suzhou Jade Biomedical Co., Ltd reportedly raised USD 10 million in a Series B...
Worg Pharmaceuticals Raises RMB 400 Million in Series B Funding
Worg Pharmaceuticals, a Hangzhou-based developer of novel allergic drugs, reportedly raised RMB 400 million (USD...
Luye Life Sciences Partners with Uzbekistan to Establish Vaccine Center
China-based Luye Life Sciences Group has struck a partnership with the Ministry of Innovation and...
Celregen Licenses Regenerative Therapy CLS001 from Japan’s Cellusion
Hangzhou Celregen Therapeutics Ltd, a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196),...
Transcenta’s First-in-Class Gremlin1 Antibody TST003 Receives FDA IND Clearance
China-based Transcenta Holding Limited (HKG: 6628) announced that its TST003, a first-in-class, high affinity humanized...